verapamil has been researched along with lomefloxacin in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.17) | 18.2507 |
| 2000's | 5 (10.87) | 29.6817 |
| 2010's | 32 (69.57) | 24.3611 |
| 2020's | 8 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Andrisano, V; Arce, MP; Badia, A; Bartolini, M; Camps, P; Clos, MV; Dafni, T; Formosa, X; Galdeano, C; Gómez, E; Huertas, O; Isambert, N; Lavilla, R; Luque, FJ; Mancini, F; Muñoz-Torrero, D; Ramírez, L; Rodríguez-Franco, MI | 1 |
| Arce, MP; Conde, S; García, AG; González-Muñoz, GC; López, B; López, MG; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Sen, S; Sinha, N | 1 |
| Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Andrisano, V; Bartolini, M; Clos, MV; Di Pietro, O; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Ramón, R; Viayna, E; Vicente-García, E | 1 |
| Clos, MV; Di Pietro, O; Espargaró, A; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sabaté, R | 1 |
| Clos, MV; Di Pietro, O; Espargaró, A; Galdeano, C; Guillou, C; Lamuela-Raventós, RM; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Ragusa, IM; Sabaté, R; Vallverdú-Queralt, A; Viayna, E | 1 |
| Huang, L; Li, X; Meng, F; Miao, H; Sun, Y | 1 |
| Artigas, A; Clos, MV; Gbedema, SY; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Sola, I; Taylor, MC; Wright, CW | 1 |
| Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Xie, SS | 1 |
| Dong, G; Guo, PP; Jiang, N; Kong, LY; Lan, JS; Li, ZR; Wang, KD; Wang, XB; Xie, SS | 1 |
| Berenguer, D; Clos, MV; Di Pietro, O; Fisa, R; Kelly, JM; Lanzoni, A; Lavilla, R; Muñoz-Torrero, D; Pérez, B; Riera, C; Sayago, H; Sola, I; Taylor, MC; Viayna, E; Vicente-García, E | 1 |
| Jiang, N; Kong, LY; Lan, JS; Li, F; Wang, J; Wang, X; Wang, ZM; Wu, JJ; Xie, SS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, P; Chen, C; Hu, K; Li, T; Liu, W; Ma, Q; Pan, W; Peng, K; Sang, Z; Yu, L; Zhang, X | 1 |
| Alencar, N; Di Pietro, O; Esteban, G; Juárez-Jiménez, J; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Sola, I; Solé, M; Szałaj, N; Unzeta, M; Vázquez, J; Viayna, E | 1 |
| Artigas, A; Clos, MV; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sola, I; Taylor, MC; Viayna, E; Wright, CW | 1 |
| Cai, P; Kong, L; Liu, Q; Wang, KDG; Wang, X; Wang, Z; Wu, J; Yang, X | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Arce, MP; Conde, S; Egea, J; Gil, C; León, R; López, MG; Monjas, L; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Ding, Y; Lan, JS; Liu, J; Liu, Y; Miao, ZY; Xie, SS; Yang, J; Zhang, T | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, HL; Yang, XL | 1 |
| Cai, P; Fang, SQ; Kong, LY; Liu, QH; Tang, YW; Wang, C; Wang, XB; Yang, HL; Yang, XL | 1 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Ganeshpurkar, A; Gupta, SK; Gutti, G; Krishnamurthy, S; Kumar, D; Modi, G; Singh, SK | 1 |
| Rai, SN; Shankar, S; Sharma, P; Shrivastava, SK; Singh, SP; Srivastava, P; Srivastava, RK; Tripathi, PN | 1 |
| Cai, P; Kong, LY; Liu, QH; Shi, CJ; Tang, YW; Wang, XB; Yang, HL; Yang, XL | 1 |
| An, B; Hu, J; Huang, L; Li, X; Li, Z; Pan, T | 1 |
| Sharma, P; Shrivastava, SK; Srivastava, P; Tripathi, PN | 1 |
| Andrisano, V; Barniol-Xicota, M; Bartolini, M; De Simone, A; Espargaró, A; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Pivetta, D; Pont, C; Sabate, R; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
| Chen, L; Chen, Y; Duan, Y; Feng, F; Huang, J; Jiang, X; Liu, C; Liu, W; Qu, W; Sun, H; Wang, Y; Zhou, J | 1 |
| Chen, T; Chen, Y; Feng, F; Jiang, X; Li, Q; Liu, C; Liu, W; Lyu, W; Sun, H; Wang, S; Wang, Y; Xing, C | 1 |
| Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Yin, FC | 1 |
| Dedecengiz, E; Erikci, A; Gokhan-Kelekci, N; Kaynak, FB; Salgin-Goksen, U; Tel, BC; Telli, G; Ucar, G; Yelekci, K | 1 |
| Ji, L; Kong, L; Li, S; Liu, X; Lu, D; Luo, H; Peng, W; Qu, L; Wang, C; Wang, X; Yin, F | 1 |
| Jaiswal, S; Raja Ayyannan, S; Tiwari, V; Uniyal, A | 1 |
| Chen, L; Lei, Z; Sun, J; Sun, X; Wang, Y; Yue, S | 1 |
| Brea, JM; Companys-Alemany, J; Griñán-Ferré, C; Johnson, JW; Kurnikova, MG; Loza, MI; Pallàs, M; Patel, DS; Pérez, B; Phillips, MB; Soto, D; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
1 review(s) available for verapamil and lomefloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
45 other study(ies) available for verapamil and lomefloxacin
| Article | Year |
|---|---|
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Drug Design; Humans; Isomerism; Membranes, Artificial; Mice; Models, Molecular; Molecular Conformation; Permeability; Protein Binding; Tacrine | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Catalytic Domain; Cattle; Cell Death; Cell Line, Tumor; Cell Survival; Cholinergic Agents; Cholinesterase Inhibitors; Esters; Glutamic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Neuroprotective Agents; Permeability; Piperidines; Protein Binding | 2009 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
Topics: Acetylcholinesterase; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Membranes, Artificial; Models, Biological; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Naphthyridines; Permeability; Protein Binding | 2014 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Structure-Activity Relationship; Tacrine; tau Proteins; Tauopathies | 2014 |
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
Topics: Acetylcholinesterase; Aminoquinolines; Amyloid beta-Peptides; Antioxidants; Catechols; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship; tau Proteins | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Indans; Inhibitory Concentration 50; Ligands; Peptide Fragments; Permeability; Protein Aggregates | 2014 |
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
Topics: Antimalarials; Antiprotozoal Agents; Humans; Molecular Structure; Structure-Activity Relationship | 2014 |
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chelating Agents; Coumarins; Drug Design; Humans; Metals; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Structure, Tertiary; Rats | 2015 |
Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.
Topics: Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Blood-Brain Barrier; Cell Survival; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; Chromans; Drug Design; In Vitro Techniques; Kinetics; Male; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; PC12 Cells; Picrates; Rats; Swine; Tacrine | 2015 |
Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
Topics: Acetylcholinesterase; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Leishmania infantum; Molecular Structure; Parasitic Sensitivity Tests; Quinolines; Rats; Structure-Activity Relationship; Trypanosoma brucei brucei; Trypanosoma cruzi | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Donepezil; Dose-Response Relationship, Drug; Drug Design; Eels; Humans; Indans; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Piperidines; Structure-Activity Relationship | 2016 |
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alkanes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Drug Evaluation, Preclinical; Ethylamines; Humans; Hydrogen Peroxide; Neuroprotective Agents; PC12 Cells; Rats | 2016 |
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Structure-Activity Relationship | 2016 |
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
Topics: Aminoquinolines; Brain; Dose-Response Relationship, Drug; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei | 2016 |
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Rats; Small Molecule Libraries; Structure-Activity Relationship | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Donepezil; Glutamates; Hippocampus; Humans; Indans; Neuroprotective Agents; Piperidines; Rats; Solid-Phase Synthesis Techniques | 2017 |
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Donepezil; Drug Design; Electrophorus; Humans; Indans; Mice; Molecular Docking Simulation; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Piperidines; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Brain Barrier; Chromones; Copper; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Protein Structure, Tertiary; Rats; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Imines; Ligands; Lipopolysaccharides; Mice; Microglia; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Salicylates; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Matrix Metalloproteinase 2; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2018 |
Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
Topics: Antioxidants; Benzoxazoles; Cholinesterase Inhibitors; Drug Design; Humans; Learning; Memory; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2019 |
Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Dimerization; Humans; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Prenylation; Rats; Resveratrol; Structure-Activity Relationship | 2019 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Ligands; Mice; Rats; Rolipram | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stress | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tacrine | 2019 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Glycogen Synthase Kinase 3; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Morris Water Maze Test; Phosphorylation; Protein Conformation; tau Proteins; Thiazoles | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Glycogen Synthase Kinase 3 beta; Humans; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured | 2021 |
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Topics: | 2020 |
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
Topics: Animals; Antidepressive Agents; Depression; Hep G2 Cells; Humans; Hydrazones; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Pyrazoles; Structure-Activity Relationship | 2021 |
Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Antioxidants; Aspartic Acid Endopeptidases; Azoles; Binding Sites; Blood-Brain Barrier; Cyclic S-Oxides; Drug Design; Humans; Interleukin-6; Isoindoles; Ligands; Mitochondria; Molecular Docking Simulation; Neuroprotective Agents; NF-E2-Related Factor 2; Organoselenium Compounds; Oxidative Stress; Peptide Fragments; Reactive Oxygen Species; Selenium; Signal Transduction; Thiadiazines | 2021 |
Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
Topics: Amidohydrolases; Analgesics; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Monoacylglycerol Lipases; Neuralgia; Semicarbazones | 2022 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Rats | 2022 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Receptors, N-Methyl-D-Aspartate | 2022 |